Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
71
Views
4
CrossRef citations to date
0
Altmetric
Case Report

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report

Yuanyang Zhao1 Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9541-9434View further author information
ORCID Icon,
Yuxing Chen1 Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1110-2411View further author information
ORCID Icon,
Huaying Huang1 Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-3628-6480View further author information
ORCID Icon,
Xi Li2 Department of Medicine, Burning Rock Biotech, Guangzhou, 510300, People’s Republic of ChinaView further author information
,
Lin Shao2 Department of Medicine, Burning Rock Biotech, Guangzhou, 510300, People’s Republic of ChinaView further author information
&
Hao Ding1 Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5761-9280View further author information
ORCID Icon
Pages 3063-3067 | Published online: 07 May 2021

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
  • Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11(8):473. doi:10.1038/nrclinonc.2014.104
  • Wang Z, Yang -J-J, Huang J, et al. Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first-and third-generation EGFR TKIs and shifts allelic configuration at resistance. J Thorac Oncol. 2017;12(11):1723–1727. doi:10.1016/j.jtho.2017.06.017
  • Arulananda S, Do H, Musafer A, Mitchell P, Dobrovic A, John T. Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non–small cell lung cancer. J Thorac Oncol. 2017;12(11):1728–1732. doi:10.1016/j.jtho.2017.08.006
  • Zhao J, Zou M, Lv J, Han Y, Wang G, Wang G. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report. Onco Targets Ther. 2018;11:5545. doi:10.2147/OTT.S170358
  • Wang X, Zhou L, Yin JC, Wu X, Shao YW, Gao B. Lung Adenocarcinoma harboring EGFR 19del/C797S/T790M triple mutations responds to brigatinib and Anti-EGFR antibody combination therapy. J Thorac Oncol. 2019;14(5):e85–e88. doi:10.1016/j.jtho.2019.01.015
  • Wang Y, Yang N, Zhang Y, et al. Brief Report: effective treatment of lung adenocarcinoma harboring EGFR-activating mutation/T790M/cis-C797S triple mutations by brigatinib and cetuximab combination therapy. J Thorac Oncol. 2020. doi:10.1016/j.jtho.2020.04.014
  • Mehlman C, Cadranel J, Rousseau-Bussac G, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019;137:149–156. doi:10.1016/j.lungcan.2019.09.019
  • Lim Z-F, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):1–18. doi:10.1186/s13045-019-0818-2
  • Suzawa K, Toyooka S, Sakaguchi M, et al. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER 2 oncogene alterations. Cancer Sci. 2016;107(1):45–52. doi:10.1111/cas.12845
  • Meedendorp AD, Ter Elst A, Hart NA, Groen HJM, Schuuring E, van der Wekken AJ. Response to HER2 Inhibition in a patient with brain metastasis with EGFR TKI acquired resistance and an HER2 amplification. Front Oncol. 2018;8:176. doi:10.3389/fonc.2018.00176
  • Liu X, Cao Y, Li Y, Duan X. Advanced lung adenocarcinoma with coexistent HER2 mutation and amplification and response to afatinib: a case report. Ann Palliat Med. 2020;9(2):483–487. doi:10.21037/apm.2020.02.14
  • Zhao J, Xia Y. Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review. JCO Precision Oncol. 2020;4(4):411–425. doi:10.1200/PO.19.00333
  • Tian R, Song X, Guo Y, et al. P1. 14–42 Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance (data updated). J Thorac Oncol. 2019;14(10):S571. doi:10.1016/j.jtho.2019.08.1193
  • Liu Y, Xiong Z-C, Sun X, et al. Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma. Transl Cancer Res. 2019;8(5):2151–2163. doi:10.21037/tcr.2019.09.35

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.